Novavax is trading at $12.42 with a +12.80% move; the cause of the October 9 rise remains unclear.
- Available coverage surfaced no clear company-specific catalyst. A premarket report also described no company-specific news, but predates the live move.
- Biotech-sector weakness, with XBI down 2.04%, runs counter to Novavax’s gain and does not explain it. No trading-volume data was provided.